Education
About Us
Working with TipRanks
Follow Us
Co-Diagnostics Inc (CODX)
NASDAQ:CODX
CODX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.23 - $1.40
Previous CloseN/A
Volume146.43K
Average Volume (3M)12.75M
Market Cap
$19.91M
Enterprise Value-$2.38M
Total Cash (Recent Filing)$13.36M
Total Debt (Recent Filing)$1.70M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Nov 06, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding48,142,582
10 Day Avg. Volume27,982,083
30 Day Avg. Volume12,748,443
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.12
Enterprise Value/Revenue-2.37
Enterprise Value/Gross Profit-5.99
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$0.50Price Target Upside31.58% Upside
Rating ConsensusHold
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNet loss was $7.7M, or ($0.23) per share, less than the estimated loss of $8.3M.
Product DevelopmentManagement expects to initiate clinical evaluations for all tests in the pipeline before the end of 2025.
Bears Say
Financial NeedsCash flows from operating activities were ($8.3M) during 2Q25, indicating the need to raise additional capital in the near term to fund operations.
Regulatory RisksThere is a risk of failure in clinical evaluations and failure to secure regulatory clearance for the instrument and/or tests in the U.S.
Co-Diagnostics News
CODX FAQ
What was Co-Diagnostics Inc’s price range in the past 12 months?
Co-Diagnostics Inc lowest stock price was $0.23 and its highest was $1.40 in the past 12 months.
What is Co-Diagnostics Inc’s market cap?
Co-Diagnostics Inc’s market cap is $19.91M.
When is Co-Diagnostics Inc’s upcoming earnings report date?
Co-Diagnostics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 39 days.
How were Co-Diagnostics Inc’s earnings last quarter?
Co-Diagnostics Inc released its earnings results on Aug 14, 2025. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.02.
Is Co-Diagnostics Inc overvalued?
According to Wall Street analysts Co-Diagnostics Inc’s price is currently Undervalued.
Does Co-Diagnostics Inc pay dividends?
Co-Diagnostics Inc does not currently pay dividends.
What is Co-Diagnostics Inc’s EPS estimate?
Co-Diagnostics Inc’s EPS estimate is -0.18.
How many shares outstanding does Co-Diagnostics Inc have?
Co-Diagnostics Inc has 48,142,582 shares outstanding.
What happened to Co-Diagnostics Inc’s price movement after its last earnings report?
Co-Diagnostics Inc reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went up 11.538%.
Which hedge fund is a major shareholder of Co-Diagnostics Inc?
Currently, no hedge funds are holding shares in CODX
Co-Diagnostics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.50 (31.58% Upside)
$0.50 (31.58% Upside)
Hedge Fund Trend
Decreased
By 36.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 11.3%
Last 30 Days ▲ 11.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.94%
12-Months-Change
Fundamentals
Return on Equity
-63.40%
Trailing 12-Months
Asset Growth
-42.42%
Trailing 12-Months
Company Description
Co-Diagnostics Inc
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
CODX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted significant advancements in Co-Diagnostics' Co-DX PCR platform development, supported by major grants and upcoming clinical evaluations. However, these positives were overshadowed by a sharp revenue decline and increased losses, indicating financial challenges.View all CODX earnings summariesCODX Stock 12 Month Forecast
Average Price Target
$0.50
▲(31.58% Upside)
Technical Analysis
Ownership Overview
5.27% Insiders
5.22% Mutual Funds
3.34% Other Institutional Investors
82.14% Public Companies and
Individual Investors